6 June 2019
Toward specific ways to combine ketamine and psychotherapy in treating depression
In major depression, remission rate in response to monoaminergic antidepressant is around 50%. The lack of strong synergies between classical antidepressants and psychotherapy may be due to the molecular effects of classical antidepressants. They modulate synapses but they do not substantially influence synaptogenesis. They also increase brain-derived neurotrophic factor (BDNF). However, for activity-dependent plasticity, BDNF …
Toward specific ways to combine ketamine and psychotherapy in treating depression Read More »
Learn more
24 June 2018
Personalized (N-of-1) Trials for Depression: A Systematic Review
Five eligible studies reporting on 47 depressed patients (range, 1-18 patients) were identified. Two studies were conducted among adults with treatment-resistant depression, 1 study among depressed inpatients, and 2 studies among patients from special populations (geriatric nursing home, human immunodeficiency virus-associated encephalopathy). All studies evaluated the effects of pharmacologic treatments (methylphenidate, D-amphetamine, ketamine, and sulpiride). …
Personalized (N-of-1) Trials for Depression: A Systematic Review Read More »
Learn more